DexCom, Inc. (NASDAQ:DXCM) Given Average Recommendation of “Moderate Buy” by Brokerages

DexCom, Inc. (NASDAQ:DXCM) has been assigned a consensus rating of “Moderate Buy” from the fifteen ratings firms that are presently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $139.33.

A number of research analysts have issued reports on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $145.00 price target on shares of DexCom in a report on Tuesday. Stifel Nicolaus decreased their price target on shares of DexCom from $145.00 to $132.00 and set a “buy” rating for the company in a report on Friday, July 12th. Raymond James raised their price target on shares of DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a report on Friday, April 26th. Morgan Stanley decreased their price target on shares of DexCom from $132.00 to $120.00 and set an “equal weight” rating for the company in a report on Monday, July 15th. Finally, UBS Group raised their price target on shares of DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th.

DexCom Trading Up 0.4 %

NASDAQ:DXCM opened at $112.13 on Wednesday. DexCom has a 52 week low of $74.75 and a 52 week high of $142.00. The firm has a 50 day moving average of $117.46 and a 200 day moving average of $124.49. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08. The stock has a market capitalization of $44.59 billion, a price-to-earnings ratio of 72.34, a PEG ratio of 2.73 and a beta of 1.16.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The company had revenue of $921.00 million during the quarter, compared to analysts’ expectations of $911.20 million. DexCom had a net margin of 16.82% and a return on equity of 31.01%. As a group, sell-side analysts anticipate that DexCom will post 1.78 earnings per share for the current fiscal year.

Insider Activity at DexCom

In related news, EVP Sadie Stern sold 427 shares of the firm’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $115.05, for a total transaction of $49,126.35. Following the sale, the executive vice president now owns 75,877 shares in the company, valued at $8,729,648.85. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other DexCom news, Director Bridgette P. Heller sold 1,000 shares of the stock in a transaction on Friday, June 14th. The shares were sold at an average price of $113.55, for a total transaction of $113,550.00. Following the transaction, the director now directly owns 25,349 shares of the company’s stock, valued at $2,878,378.95. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Sadie Stern sold 427 shares of the stock in a transaction on Monday, June 10th. The shares were sold at an average price of $115.05, for a total transaction of $49,126.35. Following the transaction, the executive vice president now directly owns 75,877 shares in the company, valued at $8,729,648.85. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 4,112 shares of company stock worth $480,861. 0.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On DexCom

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. LaFleur & Godfrey LLC lifted its holdings in DexCom by 5.2% during the second quarter. LaFleur & Godfrey LLC now owns 5,244 shares of the medical device company’s stock valued at $595,000 after purchasing an additional 261 shares in the last quarter. Stableford Capital II LLC lifted its stake in shares of DexCom by 4.8% in the second quarter. Stableford Capital II LLC now owns 4,592 shares of the medical device company’s stock worth $526,000 after buying an additional 212 shares in the last quarter. Lecap Asset Management Ltd. purchased a new position in shares of DexCom in the second quarter worth about $2,825,000. Fifth Third Wealth Advisors LLC purchased a new position in shares of DexCom in the second quarter worth about $829,000. Finally, Crescent Grove Advisors LLC purchased a new position in shares of DexCom in the second quarter worth about $249,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.